Observational studyBMC cardiovascular disorders2026

Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study.

Carl VahldieckPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.